Navigation Links
Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
Date:10/19/2007

VANCOUVER, Oct. 19 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced preliminary financial results from the third quarter ended September 30, 2007 and updated its financial outlook for the full year ending December 31, 2007, in conjunction with the release of Boston Scientific Corporation's (BSC) third quarter financial results earlier today. Angiotech will release its complete third quarter financial results, including Management's Discussion and Analysis of Financial Condition and Results of Operations, and hold its third quarter results conference call for analysts and investors, as scheduled on November 1, 2007.

Selected preliminary unaudited financial results for the third quarter are as follows:

- Total revenues were $68.0 million.

- Net product sales were $41.4 million and were derived primarily from

sales of our various single-use specialty medical devices as well as

from sales of medical device components to third parties.

- Royalty revenue was $26.6 million and included $24.9 million of

royalty revenue derived from sales by BSC of paclitaxel-eluting

coronary stent systems.

- Adjusted EBITDA (earnings before interest, taxes, depreciation and

amortization, adjusted to exclude certain non-cash and non-recurring

items) was $7.2 million. Excluding research and development expenses,

the significant majority of which are discretionary and relate

primarily to our Pharmaceutical Technologies segment, Adjusted EBITDA

would be $19.8 million.

- Cash and long-term investment
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PARIS and NEW YORK ... data from its open-label pilot study of mazindol in ... Design, Development and Therapy in December 2014 . ... of mazindol in children with attention deficit/hyperactivity disorder" ( ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) ...
(Date:12/22/2014)... 2014  Alternative Energy & Environmental Solutions, Inc., ... a letter of intent to acquire BioTechPharma Corporation, ... a nanotechnology-based development platform used to create drug ... on-site collection and testing to identify infectious disease, ... an immediate, non-invasive and cost-effective manner. ...
(Date:12/22/2014)... 22, 2014 ITRA Global, one of ... of commercial real estate, has further expanded its global ... Perth and Brisbane, Western Australia, reports Mylinda Vick, CCIM, ... ITRA Global / ACORPP (Australian Corporate Property and ... company providing property services to a wide range of ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one of the ... Maroulis, Pharm.D. to the newly created position of Vice ... position, Dr. Maroulis will continue to manage the entire ... multi-site pharmacies as the company expands. Dr. Maroulis has ... he has served in many different capacities in the ...
Breaking Biology Technology:Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3ALNE Announces Intention To Acquire BioTechPharma 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... fight cancer, rheumatoid arthritis, as well as enhance ... CEL-SCI Corporation (NYSE Amex: CVM ) ... 11th annual National Foundation of Infectious Diseases Conference ... L.E.A.P.S.(TM) (Ligand Epitope Antigen Presentation System) vaccine technology ...
... April 27 MannKind Corporation (Nasdaq: MNKD ... on Monday, May 4, 2009.Management of the Company will ... financial results and other Company developments at 4:00 PM ... will be its Chairman and Chief Executive Officer, Alfred ...
... SAN DIEGO, April 27 Cadence Pharmaceuticals, Inc. (Nasdaq: ... clinical trials of its investigational product candidate, Acetavance(TM) (intravenous ... Regional Anesthesia and Pain Medicine (ASRA) 34th Annual Regional ... and at the Society of Hospital Medicine (SHM) Annual ...
Cached Biology Technology:CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease 2CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease 3CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease 4MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 4, 2009 2Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences 2
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) ... Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this ... in biomedical applications. Chemical sensors help in recording ... during surgical procedures. The Global Chemical Sensor market ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. ... the adoption of multimodal biometric systems. Multimodal biometric ... individual for verification and identification purposes. This helps ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ... accuracy is the ultimate driver in long-term mass consumer ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... category for the largest human-designed protein, then a team of ... have designed and successfully synthesized a variant of a protein ... It is more than twice the size of the previous ... of Washington in 2003. The synthetic protein, designated FLR, ...
... A study conducted by researchers at the Johns Hopkins ... patterns of drug resistance in malaria-causing parasites taken from ... in human blood samples showed a high prevalence for ... widely used to treat malaria in the region. However, ...
... CHAPEL HILL, N.C. After a heart attack, the portions ... scar tissue. Researchers have long sought ways to avoid this ... its ability to pump blood throughout the body and eventually ... of North Carolina at Chapel Hill School of Medicine shows ...
Cached Biology News:Creation of the largest human-designed protein boosts protein engineering efforts 2Creation of the largest human-designed protein boosts protein engineering efforts 3Contrasting patterns of malaria drug resistance found between humans and mosquitoes 2Scarring a necessary evil to prevent further damage after heart attack 2
... DNA Polymerase is a premium quality recombinant ... thermostable enzyme is suitable for a wide ... highest purity and reproducible performance, each preparation ... quality control assays. NovaTaq DNA Polymerase possesses ...
... cell sorter sets a new standard for ... a revolutionary new design in instrumentation, this ... multicolor analysis. The BD FACSAria instrument is ... fixed-alignment cuvette flow cell. This new ...
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse polyclonal antibody raised against a partial recombinant IFNA13. NCBI Entrez Gene ID = 3447...
Biology Products: